Astellas’ Cresemba Review: Orphan Population With Unmet Need Vs. Limited Efficacy Data
This article was originally published in The Pink Sheet Daily
FDA’s Anti-Infective Drugs Advisory Committee will vote on whether efficacy and safety evidence support approval of Astellas’ antifungal isavuconazonium for two indications, one of which has no controlled data.
You may also be interested in...
FDA’s new drug development qualification process offers a pathway for outside groups to gain acceptance of specific biomarkers for regulatory purposes. FDA recently used the process to qualify a specific biomarker for a severe fungal infection.
Pulling the controversial Alzheimer’s drug’s BLA should not exempt Biogen from fulfilling ClinicalTrials.gov reporting requirements for two key studies, even if the research gets terminated, former head of the NIH data repository tells the Pink Sheet.
CMS Expects Part D Plans To Go To Great Lengths Facilitating Participation In New Copay ‘Smoothing’ Option
The Medicare draft guidance seems designed to ensure seniors don’t miss out on the IRA benefit.